News | March 17, 2024
Eris Lifesciences buys India formulation business of Biocon Biologics for Rs. 1,242 Cr
Both organisations enter into a long- term collaboration to expand patient access in India
Both organisations enter into a long- term collaboration to expand patient access in India
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
Pantoprazole Sodium Delayed-Release Tablets are indicated for short-term treatment of Erosive Esophagitis associated with GERD
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Minister was briefed on the nationwide dengue situation
The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Subscribe To Our Newsletter & Stay Updated
